Value of adding a polyvalent mechanical bacterial lysate to therapy of COPD patients under regular treatment with salmeterol/fluticasone

Abstract

Background: This study investigated the value of adding Ismigen^®, a polyvalent mechanical bacterial lysate, to therapy of COPD patients (FEV₁ <60% predicted) under regular treatment with salmeterol/fluticasone (SFC).

Methods: 63 patients enrolled from September to December 2007 were randomly divided into two groups (A and B). All patients were treated with salmeterol/fluticasone (SFC) 50/500 μg BID. Thirty-three subjects also received Ismigen one capsule daily the first 10 days of three consecutive months (group B). This treatment was reaped three months after the end of the first course. We assessed at inclusion and at scheduled (every 2 months) or intercurrent visit: symptoms (amount and colour of sputum, severity of dyspnoea, frequency of cough, fever), diagnosis of exacerbation, concomitant medications (antibiotics and oral corticosteroids) and hospitalization.

Results: During the course of the study two patients died. At the end of the observation period (12 months), another six patients could not be visited because they had withdrawn. Compared with SFC, adding on Ismigen reduced the total number of exacerbations (23 out of 30 patients in group A and 21 out of 33 patients in group B), the number (rate) of exacerbations per patient per year (18 out of 27 patients [0.67] in group A and 15 out of 28 patients [0.54] in group B), the number of exacerbations that needed treatment with oral corticosteroids (12 out of 23 [52%] in group A and 9 out of 21 [43%] in group B) and the total number (rate) of hospitalizations (4/30 [0.13] in group A and 3/33 [0.09] in group B). There were no significant differences between treatments with respect to their effect on the symptoms of exacerbations. A decrease in the need for antibiotics was also observed in group B.

Conclusion: Our data suggest that COPD patients benefit from the addition of Ismigen on top of the routine maintenance treatment with SFC.

Keywords

COPD exacerbations fluticasone propionate salmeterol polyvalent mechanical bacterial lysate

References

Blasi, F. (2002) Vaccinoprofilassi delle infezioni respiratorie: efficacia di un lisato batterico per via meccanica. Gior It Mal Tor 56: 85-89.

Calverley, P.M. , Anderson, J.A. , Celli, B. , Ferguson, G.T. , Jenkins, C. , Jones, P.W. et al. (2007) Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 356: 775-789.

Cazzola, M. (2006) A new bacterial lysate protects by reducing infectious exacerbations in moderate to very severe COPD: a double-blind, randomized, placebo-controlled trial. Trends Med 6: 191-199.

Cazzola, M. , Rogliani, P. and Curradi, G. (2008) Bacterial extracts for the prevention of acute exacerbations in chronic obstructive pulmonary disease: a point of view. Respir Med 102: 321-327.

Celli, B.R. and MacNee, W. (2004) Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 23: 932-946.

Centanni, S. , Pregliasco, F. , Bonfatti, C. , Mensi, C. , Tarsia, P. , Guarnieri, R. et al. (1997) Clinical efficacy of a vaccine-immunostimulant combination in the prevention of influenza in patients with chronic obstructive pulmonary disease and chronic asthma. J Chemother 9: 273-278.

Cogo, R. , Ramponi, A. , Scivoletto, G. and Rippoli, R. (2003) Prophylaxis for acute exacerbations of chronic bronchitis using an antibacterial sublingual vaccine obtained through mechanical lysis: a clinical and pharmacoeconomic study. Acta Biol Med 74: 81-87.

Hirschmann, J.V. (2000) Do bacteria cause exacerbation of COPD? Chest 118: 193-203.

Jindal, S.K. , Gupta, D. and Aggarwal, A.N. (2004) Guidelines for management of chronic obstructive pulmonary disease (COPD) in India: a guide for physicians Ind J Chest Dis Allied Sci 46: 137-153.

10.

Lanzilli, G. , Falchetti, R. , Cottarelli, A. , Macchi, A. , Ungheri, D. and Fuggetta, MP (2006) In vivo effect of an immunostimulating bacterial lysate on human B lymphocytes. Int J Immunopathol Pharmacol 19: 551-559.

11.

Martinez, F.J. (2007) Pathogen-directed therapy in acute exacerbations of chronic obstructive pulmonary disease. Proc Am Thorac Soc 4: 647-658.

12.

Rabe, K.F. , Hurd, S. , Anzueto, A. , Barnes, P.J. , Buist, S.A. , Calverley, P. et al. (2007) Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary . Am J Respir Crit Care Med 176: 532-555.

13.

Rosaschino, F. and Cattaneo, L. (2004) Strategies for optimizing compliance of paediatric patients for seasonal antibacterial vaccination with sublingually administered polyvalent mechanical bacterial lysates (PMBL). Acta Biomed 75: 171-178.

14.

Rossi, G.A. , Peri, C. , Raynal, M.E. , Defilippi, A.C. , Risso, F.M. , Schenone, G. et al. (2003) Naturally occurring immune response against bacteria commonly involved in upper respiratory tract infections: analysis of the antigen-specific salivary IgA levels. Immunol Lett 86: 85-91.

15.

Sole`r, M. (2005) Modulation of airway inflammation to prevent exacerbations of COPD. Eur Respir Rev 14: 78-82.

16.

Steurer-Stey, C. , Bachmann, L.M. , Steurer, J. and Tramer, M.R. (2004) Oral purified bacterial extracts in chronic bronchitis and COPD: systematic review. Chest 126: 1645-1655.